Gabriele Grecchi

CEO at CaSRevolution

Presenter

CaSRevolution is an Italian-based biotech developing innovative Alzheimer’s therapies by targeting the Calcium Sensing Receptor (CaSR) in astrocytes and neurons. Using Negative Allosteric Modulators, our approach blocks Abeta-triggered neurotoxicity, halting the cascade that leads to amyloid plaques, tau hyperphosphorylation, and neuroinflammation. Backed by robust preclinical data, we are advancing a novel, mechanism-based treatment to meet the unmet needs of AD patients